Eric C. Hsu - Dec 16, 2022 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Role
Sr. VP, Pre-Clinical Res/Dev
Signature
/s/ Eric A. Adams, attorney-in-fact for Mr. Eric C. Hsu
Stock symbol
INM
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/19/2022, 03:49 PM
Previous filing
Nov 18, 2022
Next filing
Mar 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INM Employee Stock Option (Right to Buy) Award $0 +4.2K +89.78% $0.00 8.88K Dec 16, 2022 Common shares 4.2K $1.78 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.
F2 On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.